BIOLINERX Ltd/S (NASDAQ:BLRX)‘s stock had its “buy” rating restated by equities researchers at Maxim Group in a report issued on Thursday. They presently have a $2.00 price objective on the biotechnology company’s stock. Maxim Group’s target price indicates a potential upside of 186.12% from the company’s previous close.
The analysts wrote, “BioLineRx reported 3Q18 with a net loss of ($6.2M) and ended the quarter with $35M in cash on the balance sheet. We estimate a runway to late 2019.””
A number of other research firms have also weighed in on BLRX. HC Wainwright set a $4.00 price objective on shares of BIOLINERX Ltd/S and gave the company a “buy” rating in a research note on Tuesday, August 7th. Zacks Investment Research raised shares of BIOLINERX Ltd/S from a “hold” rating to a “buy” rating and set a $1.00 price objective on the stock in a research note on Thursday, August 16th. MED began coverage on shares of BIOLINERX Ltd/S in a research note on Wednesday, August 1st. They issued a “market perform” rating on the stock. Finally, ValuEngine upgraded shares of BIOLINERX Ltd/S from a “hold” rating to a “buy” rating in a report on Thursday, October 4th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. BIOLINERX Ltd/S has an average rating of “Buy” and a consensus price target of $2.50.
BIOLINERX Ltd/S (NASDAQ:BLRX) last released its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06). On average, equities research analysts anticipate that BIOLINERX Ltd/S will post -0.22 EPS for the current fiscal year.
An institutional investor recently bought a new position in BIOLINERX Ltd/S stock. Fosun International Ltd bought a new stake in BIOLINERX Ltd/S (NASDAQ:BLRX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,357,415 shares of the biotechnology company’s stock, valued at approximately $1,412,000. Fosun International Ltd owned about 1.27% of BIOLINERX Ltd/S at the end of the most recent reporting period. Institutional investors own 34.69% of the company’s stock.
BIOLINERX Ltd/S Company Profile
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Featured Article: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.